PYXS
Pyxis Oncology, Inc. NASDAQ Listed Oct 8, 2021$2.26
After hrs
$2.74
+0.00%
Mkt Cap $142.0M
52w Low $0.97
28.2% of range
52w High $5.55
50d MA $1.58
200d MA $2.18
P/E (TTM)
-1.3x
EV/EBITDA
-0.9x
P/B
2.0x
Debt/Equity
0.3x
ROE
-149.1%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
1.42
50d MA
$1.58
200d MA
$2.18
Avg Volume
402.3K
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
321 HARRISON AVENUE · BOSTON, MA 02118 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23, 2026 | AMC | -0.35 | -0.29 | +17.1% | 1.42 | +1.4% | -4.2% | +0.7% | -2.1% | -7.7% | -10.6% | — |
| Nov 3, 2025 | AMC | -0.36 | -0.35 | +2.8% | 3.81 | +0.8% | +2.4% | +2.6% | +6.0% | +2.6% | +25.2% | — |
| Aug 14, 2025 | AMC | -0.36 | -0.30 | +16.7% | 1.13 | +1.8% | +8.8% | +9.7% | +6.2% | +2.7% | +16.8% | — |
| May 15, 2025 | AMC | -0.29 | -0.35 | -20.7% | 1.11 | +0.0% | +9.0% | +10.8% | +9.0% | +3.6% | +8.1% | — |
| Mar 18, 2025 | AMC | -0.33 | -0.32 | +3.0% | 1.06 | +1.9% | +0.9% | +5.7% | +14.2% | +13.2% | +8.5% | — |
| Nov 12, 2024 | AMC | -0.32 | -0.35 | -9.4% | 4.62 | +2.8% | -7.4% | -7.4% | -9.3% | -11.5% | -10.0% | — |
| Aug 14, 2024 | AMC | -0.33 | -0.29 | +12.1% | 3.36 | -0.9% | +2.1% | +0.0% | +7.7% | +5.7% | +8.0% | — |
| May 14, 2024 | AMC | -0.27 | -0.06 | +77.8% | 4.20 | +1.0% | +0.2% | -0.7% | -1.2% | -0.2% | -4.8% | — |
| Mar 21, 2024 | AMC | -0.49 | -0.33 | +32.7% | 4.96 | -0.6% | -19.6% | -26.4% | -22.8% | -15.3% | -14.1% | — |
| Nov 7, 2023 | AMC | -0.57 | -0.56 | +1.8% | 1.66 | +0.0% | -1.8% | -9.6% | -7.8% | -6.0% | -6.6% | — |
| Aug 11, 2023 | AMC | -0.66 | -0.41 | +37.9% | 2.58 | -1.9% | -5.0% | -5.4% | -7.8% | -12.8% | -15.9% | — |
| May 11, 2023 | AMC | -0.84 | -0.54 | +35.7% | 3.04 | +1.6% | +7.9% | +22.7% | +16.8% | +22.0% | +22.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5 | Wedbush | Initiates | Outperform | $6 | $1.76 | $1.88 | +6.8% | +4.0% | +30.7% | +28.4% | — | — |
| Mar 24 | Stifel | Maintains | Buy → Buy | — | $1.42 | $1.44 | +1.4% | -4.2% | +0.7% | -2.1% | -7.7% | -10.6% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.42 | $1.44 | +1.4% | -4.2% | +0.7% | -2.1% | -7.7% | -10.6% |
| Dec 19 | RBC Capital | Maintains | Outperform → Outperform | — | $1.73 | $1.75 | +1.2% | -26.6% | -31.2% | -37.0% | -35.8% | -35.8% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.75 | +1.2% | -26.6% | -31.2% | -37.0% | -35.8% | -35.8% |
| Nov 24 | Stephens & Co. | Maintains | Overweight → Overweight | — | $4.80 | $5.05 | +5.2% | +7.3% | +11.2% | +10.0% | +8.1% | -8.5% |
| Nov 4 | Guggenheim | Maintains | Buy → Buy | — | $3.81 | $3.84 | +0.8% | +2.4% | +2.6% | +6.0% | +2.6% | +25.2% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.24 | $1.23 | -0.8% | -3.2% | -6.5% | +6.5% | +8.1% | +12.1% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.17 | -3.3% | +1.7% | +0.0% | -5.0% | -0.8% | +1.7% |
| Mar 19 | RBC Capital | Maintains | Outperform → Outperform | — | $1.06 | $1.08 | +1.9% | +0.9% | +5.7% | +14.2% | +13.2% | +8.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.06 | $1.08 | +1.9% | +0.9% | +5.7% | +14.2% | +13.2% | +8.5% |
| Dec 20 | RBC Capital | Maintains | Outperform → Outperform | — | $1.54 | $1.54 | +0.0% | +9.7% | +8.4% | +3.9% | +5.2% | +3.2% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.54 | +0.0% | +9.7% | +8.4% | +3.9% | +5.2% | +3.2% |
| Nov 21 | William Blair | Downgrade | Outperform → Market Perform | — | $3.82 | $2.17 | -43.2% | -45.0% | -50.3% | -50.5% | -53.7% | -52.1% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $3.82 | $2.17 | -43.2% | -45.0% | -50.3% | -50.5% | -53.7% | -52.1% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.82 | $2.17 | -43.2% | -45.0% | -50.3% | -50.5% | -53.7% | -52.1% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $3.66 | $3.75 | +2.5% | +0.5% | +0.8% | -1.6% | -1.6% | -4.1% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.43 | $3.44 | +0.3% | -2.0% | +5.5% | +3.5% | +5.8% | +6.4% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.21 | $4.21 | +0.0% | -1.0% | -1.4% | -0.5% | -5.0% | -7.4% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.35 | $5.25 | -1.9% | -5.0% | -1.5% | -8.0% | -11.4% | -12.3% |
| Mar 22 | RBC Capital | Maintains | Outperform → Outperform | — | $4.96 | $4.93 | -0.6% | -19.6% | -26.4% | -22.8% | -15.3% | -14.1% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.96 | $4.93 | -0.6% | -19.6% | -26.4% | -22.8% | -15.3% | -14.1% |
| Mar 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $2.20 | $2.13 | -3.2% | -12.3% | +0.5% | +22.7% | +75.0% | +106.4% |
| Nov 2 | Jefferies | Maintains | Buy → Buy | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.8% | +3.3% | -8.5% | -21.3% |
| Nov 2 | Credit Suisse | Maintains | Outperform → Outperform | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.8% | +3.3% | -8.5% | -21.3% |
| Nov 2 | BofA Securities | Maintains | Neutral → Neutral | — | $13.20 | $13.14 | -0.5% | +0.8% | +2.8% | +3.3% | -8.5% | -21.3% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Pyxus Pharmaceuticals provided a year-end business update and financial results, but the vague 8-K disclosure suggests management may be withholding material information from full public disclosure, warranting investor caution.
Mar 23
8-K · 5.02
!!! Very High
Pyxis Oncology, Inc. -- 8-K 5.02: Executive Change
Pyxis Oncology appoints Tom Civik as President effective February 2, 2026, signaling potential strategic shifts in leadership and operational direction for the oncology-focused company.
Feb 6
Data updated apr 26, 2026 9:23pm
· Source: massive.com